Boston Scientific

Devices & Diagnostics

BSX scores FDA device approval for drug-eluting stent for coronary artery disease patients

Boston Scientific (BSX) received FDA device approval for its Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, a next-gen polymer drug-eluting stent. The product launches immediately in the U.S. It will be used to treat patients with coronary artery disease. The company boasts the system offers “unparalleled visibility, low recoil, exceptional radial strength and fracture resistance, […]

Devices & Diagnostics

Boston Scientific gets FDA clearance and CE Mark for embolization catheter

Boston Scientific (BSX) received FDA clearance and the CE Mark for its Direxion Torqueable Microcatheter. The catheter is the company’s newest addition to its peripheral embolization medical device technology portfolio. Radiologists use peripheral embolization to treat liver cancer and uterine fibroids, among other conditions. “It involves deliberately blocking a blood vessel to prevent blood flow to […]

presented by
Devices & Diagnostics

BSX receives CE Mark for deep brain stimulation system as dystonia treatment

Boston Scientific (BSX) announced it has received the CE Mark for its Vercise Deep Brain Stimulation System for the treatment of dystonia, “a neurological movement disorder characterized by involuntary muscle contractions.” Dystonia is the third most common movement disorder after Parkinson’s disease and essential tremor, and more than 500,000 patients in Europe have it, according […]

Devices & Diagnostics

Boston Scientific closes Bard EP acquisition

Healthcare business intelligence: Boston Scientific (BSX) closed on its acquisition of C.R. Bard‘s Bard EP Nov. 1. According to a company statement, the addition of Bard’s advanced therapeutic catheters, diagnostic catheters, electrophysiology recording systems and intracardiac access devices will help BSX address the $2.5 billion EP market, which is growing by as much as 10 percent yearly. […]

Devices & Diagnostics

Two top medical device companies announce promising renal denervation tech results

Two top medical device companies turned up the heat on the renal denervation competition. Both Boston Scientific (BSX) and St. Jude Medical (STJ) delivered promising results from studies on their two respective renal denervation technologies at the Transcatheter Cardiovascular Therapeutics conference in San Francisco. Such technology uses radiofrequency ablation on the nerves leading to the […]

Devices & Diagnostics

BSX scores CE Mark for Lotus Valve System for patients with severe aortic stenosis

Boston Scientific (BSX) announced the medical device company has received a CE Mark for its Lotus Valve System, which offers alternative treatment for high-risk patients with sever aortic stenosis. The advanced transcatheter aortic valve replacement (TAVR) technology, the company claims, is “the only aortic valve device that can be assessed in its final position prior […]

Devices & Diagnostics

BSX to pay $30M to end allegations Guidant sold defective defibrillators to Medicare

Guidant continues to prove itself as Boston Scientific’s biggest legal headache. Reuters reports Boston Scientific (BSX) has agreed to pay a $30 million settlement to bring two-year civil lawsuit, and with it allegations that Guidant knowingly sold defective defibrillators used in Medicare patients, to an end. BSX bought Guidant in 2006. Guidant sold the defibrillators, which […]

Devices & Diagnostics

FDA grants Neuros Medical IDE approval to conduct clinical trial for pain management technology for amputees

Neuros Medical, a Cleveland-based medical device company, received an FDA investigational device exemption approval to begin a clinical study on its technology for intractable limb pain management for amputees. According to the company website, the Altius System High Frequency Nerve Block technology “consists of an electrode (also known as a lead) placed around a peripheral […]